Pharmaceutical Technology

NOVEMBER 24, 2022

Few contract development and manufacturing organizations (CDMOs) are able to provide radiolabeling services as part of a fully integrated pharmaceutical development program. How does your unique Synthesis-to-Clinic® offering streamline the drug development process?

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

Pharmaceutical Technology

AUGUST 22, 2022

Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. They also offer enhanced bioavailability, exact dosing and an extended shelf life. Compared to traditional hard capsules or granules, they are easier to swallow and more attractive in appearance.

Compliance 130

Compliance Bioavailability Containment Branding 130

XTalks

FEBRUARY 25, 2022

After five years of research and development, the brand found a way to transform saved grain from brewing into nutrient-rich, barley-based proteins and fibers that have a variety of applications in the food and beverage industry. EverGrain’s UFA Certification. Related: Will Pecan Milk Find Success in the Crowded Plant-Based Dairy Space?

Production 98

Production Protein Branding Bioavailability 98

XTalks

JUNE 14, 2023

Sheppard, MD, MMSc, FACS, professor of ophthalmology at Eastern Virginia Medical School, and mid-atlantic medical director for Eye Care Partners and investigator in the development program. Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

Pharmaceutical Technology

MAY 10, 2023

Within the pharmaceutical industry, it is critical to measure particle size as it influences surface area and porosity, impacting a drug’s bioavailability, effectiveness, and shelf life. Particle size is monitored in quality control as well as the development of active pharmaceutical ingredients (APIs).

Contamination 130

Contamination Filler Bioavailability Production 130

Pharmaceutical Technology

APRIL 12, 2023

Evidence suggests that API manufacturing is gaining in complexity, as well as sophistication, and therefore adding to the risk profile of drug development. Of 2,787 small molecule API CMOs analysed by GlobalData in 2021, only a third offered containment capabilities, and only 256 facilities (9%) featured controlled substance capabilities.

Manufacturing 130

Manufacturing Production Containment Contamination 130

The Pharma Data

DECEMBER 29, 2020

Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions.

Life Science 52

Life Science Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Development Bioavailability 52

The Pharma Data

JANUARY 20, 2021

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. About Calliditas. Forward-Looking Statements.

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 3, 2021

Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services.

Containment 40

Containment Bioavailability Clinical Trials Clinical Trials 40

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. To build the database, they gathered data from previously published papers and pharmaceutical patents.

Drugs 40

Drugs Protein Bioavailability Research 40

The Pharma Data

JANUARY 27, 2021

Development of oral biosensor and contract development & manufacturing. Psychedelic transdermal and sublingual drug formulation development. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

NOVEMBER 17, 2020

The strong results from this Phase 1 readout reinforce our view that LYT-100 has the potential to offer a tolerability and bioavailability profile that could be highly differentiated at the same exposure levels as pirfenidone,” said Daphne Zohar, co-founder and chief executive officer of PureTech. About PureTech Health.

Production 52

Production Trials Bioavailability Drugs 52

FDA Law Blog

JANUARY 23, 2023

More recently, in April 2022, the agency issued draft guidance recommending sponsors to develop Diversity Action Plans to improve the enrollment of racial and ethnic populations in clinical trials. Now, FDORA makes these plans mandatory for most drug and device studies.

Trials 59

Trials Clinical Trials Clinical Trials Drugs 59

The Pharma Data

OCTOBER 21, 2020

We designed KB-0742 to be an orally bioavailable CDK9 inhibitor with a differentiated selectivity profile,” said Norbert Bischofberger, Ph.D., We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”.

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40

The Pharma Data

DECEMBER 3, 2020

Achieving the primary endpoint of the SOLSTICE trial is an exciting new development in the search for a treatment for transplant recipients with refractory/resistant CMV infection. No new safety signals were identified and maribavir was associated with lower incidence of neutropenia compared to IAT. About Maribavir.

Drugs 52

Drugs Medicine Trials Development 52